Anti-MuSK myasthenia gravis with prolonged remission

Bouwyn, Jean Paul; Magnier, P; Bédat-Millet, Anne-Laure; Ahtoy, Patrick; Maltête, David; Lefaucheur, Romain

doi:10.1016/j.nmd.2016.04.008

Cited by 11 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Now that MuSK‐MG is more readily recognized, more reports of a relatively benign course and long remission are being encountered . With timely, well‐chosen, and appropriately aggressive therapy, most patients with MuSK‐MG ultimately achieve an MM status or better.…”

Section: Treatmentmentioning

confidence: 99%

Myasthenia gravis with muscle‐specific tyrosine kinase antibodies: A narrative review

Morren

2018

Muscle and Nerve

View full text Add to dashboard Cite

Growing evidence provides new insights about myasthenia gravis (MG) with antibodies against muscle-specific tyrosine kinase (MuSK-MG), including its pathogenesis, clinical and electrophysiological manifestations, and treatment. Data now support the presence of both presynaptic and postsynaptic dysfunction in MuSK-MG. This is 1 of many key differences between MuSK-MG and acetylcholine receptor antibody-MG (AChR-MG), especially as it pertains to potential therapeutic implications. In comparison to AChR-MG, MuSK-MG is generally more refractory to treatment. However, because MuSK-MG is better understood and more readily recognized today, there are more reports of a relatively benign course. The most effective immunotherapies for MuSK-MG are corticosteroids, plasmapheresis, and rituximab. With appropriate therapy, most patients with MuSK-MG achieve minimal manifestation status or better on the postintervention status outlined by the Myasthenia Gravis Foundation of America. A minority of patients remain refractory to treatment, and optimal management for this group remains a considerable challenge. Muscle Nerve 58: 344-358, 2018.

show abstract

Section: Treatmentmentioning

confidence: 99%

Myasthenia gravis with muscle‐specific tyrosine kinase antibodies: A narrative review

Morren

2018

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…With MG, the acetylcholine substance is attacked by anti-acetylcholine receptors, which leads to the decrease in muscle activity. Another source that could contribute to the manifestation of MG is the anti-muscle-specific tyrosine kinase (anti-MuSK), which also impacts the neuromuscular junction site [3,4]. The MuSK receptor is required for maintaining the neuromuscular junction as well as its formation during fetal development [5].…”

Section: Myasthenia Gravismentioning

confidence: 99%

“…4: LOO cross validated classification accuracy using Group All with mean SBE feature (Morlet Wavelet).Table 4.5: LOO cross validated classification accuracy using Group MSLT with mean SBE feature (Morlet Wavelet). Table 4.6: LOO cross validated classification accuracy using Group PSG with mean SBE feature (Morlet Wavelet).…”

mentioning

confidence: 99%

Analysis of electrooculogram (EOG) signals in studying myasthenia gravis

Liang¹

2021

Preprint

View full text Add to dashboard Cite

Myasthenia Gravis (MG) is a neuromuscular disorder that induces muscle weakness and fatigue which can be fatal. A common precursor for severe form of MG is ocular MG. In this thesis, we explored signal processing methodologies for early stage detection of MG using electrooculogram (EOG) signals. An EOG signal database consisting of 62 control and 16 MG (mild to moderate) subjects were analyzed for eye movement characteristics and EOG signal morphologies using time domain and wavelet domain techniques. A linear discriminant analysis (LDA) based classifier was used to quantify the ability of features in separating MG from control samples. Average overall classification accuracy achieved by the proposed method for the best time domain feature (average rise rate) and best wavelet feature (scale band energy) was 82.5% (P<0.01, AUC=0.887) and 83.8% (P<0.01, AUC=0.893), respectively. The obtained results suggest EOG based analysis is a viable, non-invasive alternative MG screening method.

show abstract

“…There is a report of a patient responding to high dose cyclophosphamide at 50mg/kg for 4 days who had failed other therapies including rituximab 148 . There have also been reports of patients going into spontaneous remission 149 .…”

Section: Musk Antibody-positive Mgmentioning

confidence: 99%

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies

et al. 2018

View full text Add to dashboard Cite

Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.

show abstract

Anti-MuSK myasthenia gravis with prolonged remission

Cited by 11 publications

References 6 publications

Myasthenia gravis with muscle‐specific tyrosine kinase antibodies: A narrative review

Myasthenia gravis with muscle‐specific tyrosine kinase antibodies: A narrative review

Analysis of electrooculogram (EOG) signals in studying myasthenia gravis

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies

Contact Info

Product

Resources

About